Skip to main content

Table 1 Summary of the number of piglets with clinical signs and S. suis isolation.

From: Experimental evaluation of protection and immunogenicity of Streptococcus suis bacterin-based vaccines formulated with different commercial adjuvants in weaned piglets

 

Locomotion

CNS/other severe clinical signs

S. suis in blood

Total S. suis isolation

Group 1, Alhydrogel®

    

Vaccine

8/9a

6/10

6/8b

8/10

Placebo

10/10

6/10

5/8b

9/10

Group 2, Emulsigen®-D

    

Vaccine

8/9c

7/9c

7/9c

7/9c

Placebo

9/9a

7/10

8/9b

9/10

Group 3, Quil-A®

    

Vaccine

10/10

8/10

5/10

10/10

Placebo

10/10

6/10

5/10

8/10

Group 4, Montanide™ ISA 206

    

Vaccine

7/10

6/10

4/10

6/10

Placebo

9/9a

9/10

7/9b

9/10

Group 5, Montanide™ ISA 61

    

Vaccine

7/10

0/10

0/10

3/10

Placebo

10/10

7/10

7/10

9/10

Group 6, Montanide™ ISA 201

    

Vaccine

8/9a

4/10

2/9b

9/10

Placebo

7/7a

7/10

2/7b

10/10

  1. a Piglets died at Day 1 thus locomotion signs could not be collected.
  2. b Blood could not be collected from one or more animals.
  3. c One piglet in the vaccine group died before the second vaccination due to causes not related to the S. suis infection.